Business Context and Reporting Period
Company: Denali Therapeutics Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2024
Business Overview: Denali is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutics for neurodegenerative and lysosomal storage diseases. The company utilizes its proprietary Transport Vehicle (TV) platform to deliver large molecules across the blood-brain barrier. As of June 30, 2024, the company had no approved products and no product revenue.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2024 |
Six Months Ended June 30, 2024 |
Six Months Ended June 30, 2023 |
|---|---|---|---|
| Collaboration Revenue | $0 | $0 | $329,264 |
| Operating Expenses | $116,593 | $248,845 | $279,596 |
| Net Income (Loss) | $(99,026) | $(200,828) | $73,602 |
| Diluted EPS | $(0.59) | $(1.26) | $0.52 |
| Cash, Cash Equivalents & Marketable Securities | $1,346,038 (as of June 30, 2024) | ||
| Accumulated Deficit | $1,317,039 (as of June 30, 2024) |
Liquidity: As of June 30, 2024, the company held $74.7 million in cash and cash equivalents and $1.27 billion in marketable securities. Management believes these resources are sufficient to fund operations for at least the next twelve months.
Material Changes vs. Prior Period
- Revenue Decline: Collaboration revenue dropped to zero for the three and six months ended June 30, 2024, compared to $294.1 million and $329.3 million in the same periods of 2023. This decrease is primarily due to the recognition of $293.9 million in revenue in April 2023 from Biogen exercising an option to license the ATV:Abeta program, and the absence of similar milestone events in 2024.
- Operating Expenses: Total operating expenses decreased by approximately 11% year-over-year for the six-month period ($248.8 million in 2024 vs. $279.6 million in 2023). This reduction was driven by lower personnel costs following the divestiture of preclinical small molecule programs and decreased external expenses for discontinued programs (ATV:TREM2 and PTV:PGRN).
- Net Loss: The company reported a net loss of $200.8 million for the six months ended June 30, 2024, compared to net income of $73.6 million in the prior year period, largely due to the absence of collaboration revenue.
- Divestiture Gain: The company recognized a non-cash gain of $14.5 million in the first half of 2024 from the divestiture of certain preclinical small molecule programs to a venture-backed private company.
Guidance, Outlook, and Management Commentary
- Financing Activity: In February 2024, Denali completed a private placement raising approximately $499.3 million through the sale of common stock and pre-funded warrants. Proceeds are intended to support R&D and the expansion of the BBB-crossing TV technology.
- Collaboration Updates:
- Biogen: In July 2024 (post-period), Biogen terminated its license to the ATV:Abeta program. All rights reverted to Denali. The LRRK2 collaboration remains active, with a new $75 million funding agreement for a Phase 2a study in Parkinson's disease.
- Sanofi: The Phase 2 HIMALAYA study for SAR443820/DNL788 in ALS did not meet its primary endpoint in February 2024. However, the Phase 2 study in Multiple Sclerosis remains fully enrolled and ongoing.
- Takeda: The Phase 1/2 study for TAK-594/DNL593 in FTD-GRN was paused in January 2024 for protocol modifications; prescreening for the amended cohort is ongoing.
- Key Programs:
- ETV:IDS (DNL310): Enrollment in the Phase 1/2 study for Hunter syndrome is complete. The FDA has indicated openness to discussing an accelerated approval pathway using CSF heparan sulfate as a surrogate biomarker.
- DNL343 (eIF2B): Enrollment is complete in the Phase 2/3 HEALEY ALS Platform Trial.
- DNL126 (ETV:SGSH): Selected for the FDA's START Pilot Program to accelerate development for Sanfilippo syndrome Type A.
- Risks: The company faces significant risks related to the uncertainty of clinical trial outcomes, the need for additional capital, reliance on third-party manufacturers, and the potential for collaboration terminations. The company expects to continue incurring significant operating losses for the foreseeable future.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $1.35 billion cash position against projected burn rates, considering the lack of product revenue.
- Biogen Termination Impact: Assess the financial and strategic implications of the July 2024 termination of the ATV:Abeta license with Biogen and the reversion of rights to Denali.
- Clinical Trial Status: Monitor the progress of the amended protocol for the TAK-594/DNL593 (FTD-GRN) study and the upcoming data readouts for DNL126 and ETV:IDS.
- Divestiture Consideration: Review the terms of the $15 million SAFE (Simple Agreement for Future Equity) received from the divestiture of small molecule programs and the potential for future milestone payments.
- Manufacturing Capabilities: Evaluate the progress and risks associated with the build-out of the internal manufacturing facility in Salt Lake City, Utah.